Article

Intracorneal inlay now available in Canada

AcuFocus Inc. has received approval from Health Canada to market and sell the Kamra inlay, an innovative corneal inlay to treat presbyopia, within Canada.

Irvine, CA-AcuFocus Inc. (www.AcuFocus.com) announces that it has received approval from Health Canada to market and sell its corneal inlay for the treatment of presbyopia (Kamra) within Canada.

The company announced further that it has received a certificate of free sale, which will now open up additional markets, such as Argentina, Russian Federation, Venezuela, Peru, Mexico, India, and Colombia. The inlay is a unique treatment option that uses small-aperture optics to restore near and intermediate vision.

“We are excited to bring the [inlay] to surgeons in Canada so they can offer a sound solution to their [patients with presbyopia],” said Ed Peterson, AcuFocus president and chief executive officer. “We are striving to make the [inlay] available . . . around the world; with our CE Mark, certificate of free sale, and now approval from Health Canada . . . , we are one step closer to achieving that goal.”

To date, the inlay has been implanted in more than 15,000 patients and is now available in more than 40 countries worldwide. The inlay has received the CE Mark and is available in select markets across Europe, the Asia‐Pacific region, the Middle East, and South America. The company anticipates submitting for FDA Approval for distribution in the United States this year.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.